Science behind phase I clinical trials: targeting tumour cell development pathways
Science behind phase I clinical trials: targeting tumour cell development pathways
ASCO 2013 highlights
Crizotinib superior to chemo for advanced ALK positive NSCLC
Comment on progression free survival in lung cancer patients and the GALAXY-1 trial
Ganetespib inhibits Hsp90 with docetaxel for advanced lung cancer
Nivolumab with peptide vaccine in patients naive to or that failed ipilimumab
Nivolumab blocking PD1 in lung cancer and melanoma
Crizotinib and molecular testing in advanced non small cell lung cancer
Nintedanib in combination with standard second line therapy in lung cancer
Ganetespib inhibits Hsp90 effective as second-line therapy with docetaxel for advanced lung cancer
New targets for squamos cell carcinoma
Surgery in mesothelioma